Abstract
Two siblings were found to have elevated plasma concentrations and increased urinary excretion of uracil (U) and thymine (T) (as high as 50 times normal for U and 100 times normal for T, when compared to 17 healthy adult controls). The female sibling developed severe neurotoxicity after chemotherapy with 5-fluorouracil (5-FU) for breast cancer. Both had normal serum and urinary uric acid concentrations and also normal urinary orotic acid levels. Thymidine kinase activity in the female's WBC was normal 17.30 pmoles/mg protein/min (controls 19.37±7.02). Three other members of the family (mother and two other siblings) had normal plasma and urine levels of U and T.
This metabolic aberration can be explained by the decreased degradation of U, T and 5-FU in the liver. Degradation of pyrimidine bases could not be demonstrated in normal fibroblasts. The activity of dihydropyrimidine dehydrogenase was assayed in rat liver. 5-FU was found to be a substrate for this enzyme in vitro. We postulate that the two siblings have a defect in hepatic dihydropyrimidine dehydrogenase causing decreased degradation and enhancement of 5-FU toxicity in one sibling.
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tuchman, M., Stoeckeler, J., Kiang, D. et al. 419 FAMILIAL PYRIMIDINEMIA AND PYRIMIDINURIA, A NEW PHARMACOGENETIC DISORDER?. Pediatr Res 19, 180 (1985). https://doi.org/10.1203/00006450-198504000-00449
Issue date:
DOI: https://doi.org/10.1203/00006450-198504000-00449
